Telithromycin

Drugs

Volumn 61, Issue 6, 2001, Pages 815-829

  Barman Balfour, J A ^a   Figgitt, D P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME AXETIL; CLARITHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; KETOLIDE; LEVONORGESTREL; MAGNESIUM HYDROXIDE; PAROXETINE; PENICILLIN V; RANITIDINE; TELITHROMYCIN; TROVAFLOXACIN; WARFARIN;

AGE; ANTIMICROBIAL ACTIVITY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; GENDER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; NAUSEA; NEUTROPHIL; NONHUMAN; PNEUMONIA; TONSILLITIS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0034980950     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161060-00016     Document Type: Article

References (97)

1. New research in macrolides and ketolides since 1997
2. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics
3. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
4. High in vitro susceptibility of the ketolide telithromycin (HMR 3647) in clinical isolates of key respiratory pathogens [abstract no. 2224]
5. Antipneumococcal activity of telithromycin by agar dilution, microdilution, Etest, and disk diffusion methodologies
6. Tentative interpretive criteria for HMR 3647 disk diffusion susceptibility tests [abstract no. 1.01]
7. Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP) [abstract no. 1388]
8. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
9. Distribution of erythromycin A resistance determinants in Spanish Streptococcus pneumoniae isolates and comparative activity of telithromycin (HMR 3647) [abstract no. 2157]
10. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristindalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)
11. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae
12. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
13. In vitro antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens [abstract no. 1.11]
14. Telithromycin is highly active against clinical isolates of Streptococcus pneumoniae collected in the PROTEKT study, irrespective of penicillin, macrolide or fluoroquinolone resistance [abstract no. P1253]. 11th European Congress on Clinical Microbiology and Infectious Diseases; 2001 Apr 1-4; Istanbul
15. Activity of telithromycin (HMR 3647) against erythromycin-susceptible and -resistant isolates of Streptococcus pneumoniae and Streptococcus pyogenes from Austria [abstract no. 2145]
16. Activity of telithromycin (HMR 3647) against 599 S. pyogenes from ten central and eastern European countries [abstract no. 2153]
17. The comparative in vitro activity of telithromycin (HMR 3647) against isolates of Streptococcus pyogenes (Lancefield Serogroup A) circulating in Great Britain, Northern Ireland and the Republic of Ireland during late 1999 [abstract no. 2149]
18. Mechanism of macrolide resistance in Streptococcus pneumoniae and Streptococcus pyogenes from central and eastern European countries [abstract no. 0138]
19. The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent
20. Antimicrobial activity of RU-66647, a new ketolide
21. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates [abstract no. F-116 and poster]
22. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals
23. Comparative in vitro activity of HMR 3647, a new ketolide antibiotic, against S. aureus (SA) and coagulase negative staphylococci (CNS) [abstract no. F-111 and poster]
24. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci
25. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
26. Comparative activities of telithromycin (HMR 3647), levofloxacin and other antimicrobial agents against human mycoplasmas
27. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan
28. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
29. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
30. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
31. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4
32. Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin
33. Telithromycin (TEL): Assessment of susceptibility testing [abstract no. 321]
34. HMR 3647 activity against penicillin- and erythromycin-sensitive and -resistant Streptococcus pneumoniae in a two-compartment in vitro dynamic model that mimics human pharmacokinetics [abstract no. M 302]
35. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens
36. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay
37. In vitro bactericidal activity of HMR 3647 against respiratory tract pathogens [abstract E-133]
38. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect
39. In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (telithromycin) against Chlamydia pneumoniae
40. Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila
41. Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004
42. Ketolide treatment of Haemophilus influenzae experimental pneumonia
43. HMR 3647; activity against erythromycin-resistant pneumococci and Haemophilus influenzae in murine pneumonia models [abstract no. F-260]
44. HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae
45. In vivo antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens [abstract F-257]
46. HMR 3647: Activity against Legionella pneumophila serogroup 1 (Lp1) in monocyte-derived macrophages and in experimental guinea pig infection models [abstract no. B-47]
47. In vivo pharmacodynamic activity of HMR 3647, a new ketolide [abstract no. F-255]
48. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae [abstract no. 2141]
49. Recent developments in macrolides and ketolides
50. Ketolides lack inducibility properties of MLS, resistance phenotype
51. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
52. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status
53. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
54. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora
55. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses
56. Pharmacokinetics of 800mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers [abstract no. A-49]
57. Oral bioavailability of the ketolide telithromycin (HMR 3647) is similar in both elderly and young subjects [abstract no. MoP250]
58. The bioavailability of HMR 3647, a new once-daily ketolide antimicrobial, is unaffected by food [abstract no. P69]
59. Telithromycin (HMR 3647) penetrates rapidly into tonsillar tissue achieving high and prolonged tonsillar concentrations
60. HMR 3647 achieves high and sustained concentrations in broncho-pulmonary tissues [abstract no. P78]
61. The ketolide antimicrobial, telithromycin (HMR 3647) achieves high and sustained concentration in alveolar macrophages and bronchoalveolar epithelial lining fluid in healthy Japanese volunteers [abstract no. 2143]
62. Penetration of telithromycin (HMR 3647) into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses [abstract no. 658]
63. Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology [abstract no. 2144]
64. Penetration of the ketolide, HMR 3647, in cantharidin-induced blister fluid [abstract no. A-47]
65. HMR 3647 achieves high and sustained concentrations in white blood cells in man [abstract no. P79]
66. The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells
67. HMR 3647, a new ketolide antimicrobial, is metabolised, and excreted mainly in faeces in man [abstract no. P63]
68. Data on file. Ketek™ (telithromycin)
69. Pharmacokinetic profile of HMR 3647 800 mg once-daily in elderly volunteers [abstract no. P66]
70. Telithromycin (HMR 3647), the first ketolide antimicrobial, does not require dosage adjustment in individuals with hepatic impairment [abstract no. MoP249]
71. Population pharmacokinetics support the convenient once-daily 800 mg dosage of telithromycin in patients with upper and lower RTIs, including special populations [abstract no. P1263]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1-4; Istanbul
72. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
73. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia
74. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of communityacquired pneumonia
75. Efficacy of telithromycin (HMR 3647), a new once-daily antimicrobial, in the treatment of community-acquired pneumonia [abstract no. 2245]
76. Efficacy and tolerability of telithromycin (HMR 3647) vs high-dose amoxicillin in the treatment of community-acquired pneumonia [abstract no. 2244]
77. Oral telithromycin (HMR 3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community-acquired pneumonia (CAP) in adults [abstract no. 2227]
78. Efficacy of telithromycin (HMR 3647) in the treatment of bacteremia associated with community-acquired pneumonia [abstract no. 2223]
79. Data on file. Ketek™ (telithromycin)
80. Efficacy of telithromycin (HMR 3647), a new once-daily ketolide, in community-acquired pneumonia caused by atypical pathogens [abstract no. 2225]
81. Data on file. Ketek™ (telithromycin)
82. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis in patients with COPD [abstract no. 2241]
83. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis [abstract no. 2243]
84. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well tolerated and as effective as oral clarithromycin 250 mg twice daily for 10 days in group A-hemolytic streptococcal (GABHS) pharyngitis/tonsillitis [abstract no. 2229]
85. Efficacy of 5 days' telithromycin (HMR 3647) vs 10 days' penicillin V in the treatment of pharyngitis in adults [abstract no. 2242]
86. Clinical and bactriological efficacy of telithromycin (HMR 3647) in the treatment of community-acquired RTIs caused by S. pneumoniae with reduced susceptibility to penicillins or macrolides [abstract no. P1261]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr I-4; Istanbul
87. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid 500/125 mg three-times daily for 10 days in acute maxillary sinusitis (AMS) in adults [abstract no. 2226]
88. Data on file. Ketek™ (telithromycin)
89. Effect of telithromycin on ventricular repolarization in healthy subjects [abstract no. 651]
90. HMR 3647, a new ketolide antimicrobial, does not inhibit cytochrome P450 activity in vitro [abstract no. P95]
91. Data on file. Ketek™ (telithromycin)
92. Telithromycin (HMR 3647) does not interact with the CYP2D6 substrate paroxetine [abstract no. P1268]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1-4; Istanbul
93. HMR 3647, a new ketolide antimicrobia, does not affect the pharmacodynamics or pharmacokinetics of warfarin in healthy adult males [abstract no. 81]
94. HMR 3647, a new ketolide antimicrobial, does not affect the reliability of lowdose, triphasic oral contraceptives [abstract no. 10]
95. Effect of gastric pH on the bioavailability of telithromycin (HMR 3647) [abstract no. P1269]. 11th European Congress of Clinical Microbiology and Infectious Diseases; 2001 Apr 1-4; Istanbul